Lilly Ventures
Eli Lilly's investment arm, part of its Lilly Catalyze360 programme for early biotech companies. It co-invests with venture syndicates across all disease areas, including cancer.
Overview
Lilly Ventures is described on Lilly's Catalyze360 page as 'our global investment arm', one of the pillars (with Lilly Gateway Labs, Lilly ExploR&D and Lilly TuneLab) 'built to engage biotechs at the earliest stages and agnostic of therapeutic area'. The page says Lilly Ventures 'makes investments to move the innovation needle in novel areas of science, extending to health tech, emerging platforms and other impact initiatives' and deploys 'customized engagement models to co-invest with world-class syndicate partners'. The lillyventures.com domain now redirects to Lilly's partnering site, and the fetched pages do not list portfolio companies, so no oncology portfolio examples are cited. Lilly's own oncology strategy (radiopharmaceuticals, KRAS, protein degraders) suggests the venture arm's cancer exposure, but this was not confirmed from a fetched page.
Portfolio in OnCo (1)
Filter the startups table| Company | Stage | Type | Cancers | Latest round |
|---|---|---|---|---|
| Firefly Bio South San Francisco, CA, US | Acquired | biotech | Acquisition 2026, $1B |
Notes
top- lillyventures.com redirects to lilly.com/science/partners. Founding year and portfolio not stated on fetched pages. Indianapolis follows Lilly's headquarters.